ERBB2 and breast carcinoma: The July 10, 2016, article by Denduluri, et al, entitled “Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline” (J Clin Oncol 34: 2416-2427, 2016), contained an error.